I love my new Ozempic body and I'd take the shots all over again — but there's one unsettling downside
She's tying up loose ends.
Amy Kane is a poster girl for trendy weight loss shots like Ozempic, having dropped from a size 24 to a size 4 in less than two years while on the pricey jabs.
But the mom of three's eyebrow-raising journey, starting at 300 lbs. and going all the way down to 135 lbs., wasn't without its drawbacks.
Kane, 34, loves the confidence-boosting comments and a perceived difference in the way people treat her in public — but underneath her new skinny clothes, she's struggling to sort out the excess of saggy skin hanging around her midsection like a bad memory.
And Kane, who has become something of a viral sensation on social media for her dramatic 'before and after' photos, has been showing off her stubborn middle — to help other newly-skinny types struggling with the problem feel comfortable discussing the lesser-known side effect of the pricey jabs.
Dr. Siamak Agha, a board-certified plastic surgeon based in Newport Beach, California, told the Daily Mail that there has been an uptick in the number of patients coming in for excess skin removal after finding success on drugs like Zepbound and Wegovy.
Besides the stomach, Agha said, patients are presenting with extra skin around their faces and necks, as well as significant droopage in the posterior area.
And while Kane is lucky that her problem can easily be covered up by her new designer duds, underneath, she's still struggling to shrink her stomach down.
She said she moisturizes daily and has also leaned on a treatment called Neveskin, which is said to tighten the skin by giving it the hot and cold treatment.
But you won't hear Kane speaking negatively of her situation.
'I'll take this all day because my health has got a lot better,' she said.
Buying the right clothes certainly helps, the thinfluencer recently told The Post.
'Invest in your health by buying yourself a dress or a pair of jeans that make you feel good,' she said.
'That's part of the weight loss process and feeling good in your new body.'
Throughout her rapid transition, Kane admitted, she found herself purchasing clothes 'three sizes too big.'
'But I've always loved fashion, and I'm happier now that I can go into any store and find great options for my body,' she explained, revealing that she'd recently snagged some leather pants — paired with calf-clinging fall boots.
'Shopping can still be a little triggering,' she admitted.
'But now, it's way less anxiety-inducing.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Eli Lilly Just Made Another Move to Dominate the Weight Loss Market: Should You Buy the Stock?
Eli Lilly made a move that could help address a drawback of its anti-obesity medicines. This could help it fend off mounting competition in this fast-growing area. Lilly's business extends far beyond this highly lucrative market. 10 stocks we like better than Eli Lilly › Eli Lilly (NYSE: LLY) is one of the undisputed leaders in the fast-growing market for weight-management medicines. Following recent clinical wins, the company may even be taking the lead ahead of its only real competitor in the field, Novo Nordisk. However, Lilly is not taking its foot off the pedal; it just made a move that could improve its already solid position in this space. Let's figure out whether this new development makes the company's shares even more attractive. There is no questioning the efficacy of Eli Lilly's Zepbound, its leading weight-management medicine. The therapy posted excellent results in clinical trials, and has now been in use in real-world settings long enough to confirm its clinical profile. However, the treatment is administered via subcutaneous injection once weekly. Furthermore, evidence suggests that the medicine's efficacy wanes after people stop taking it, and they often regain much of the weight they had lost. So for optimal benefits, it's best to stay on the drug for a while, which is bothersome considering the dosing schedule of weekly injections. Weight-management leaders like Eli Lilly have been seeking a solution to this problem, and the healthcare specialist may have made an important step in that direction. On June 3, Camurus, a Sweden-based pharmaceutical company, announced that it had signed a deal to provide Lilly its proprietary FluidCrystal technology, designed for the long-acting delivery of medicines. Camurus' technology can deliver therapies for days to months, thanks to a lipid solution injected with a syringe or autoinjector pen, which slowly releases the drug once it comes in contact with bodily fluids or body tissue. Eli Lilly will seek to use this tech with up to four of its GLP-1 medicines. The pharmaceutical giant will pay Camurus $290 million up front, with potential additional payments of up to $580 million in clinical, regulatory, and sales milestones, as well as royalties. If Eli Lilly can incorporate Camurus' FluidCrystal technology, its GLP-1 medicines might no longer need once-weekly dosing. That should make them more attractive and boost their already impressive sales. Of course, there is more work to be done with this project, but it's worth pointing out that Lilly has already found another solution (of sorts) for this issue. The company recently reported positive phase 3 clinical trial results for orforglipron, an investigational GLP-1 medicine. Orforglipron is taken orally once a day -- a far better option for many patients. Eli Lilly continues to find ways to fend off the increasingly stiff competition in this market. Several companies are working on oral formulations of GLP-1 therapies. Others are looking into long-acting weight-management options. Biotech giant Amgen reported positive but somewhat mixed data from a phase 2 study of MariTide, a once-monthly anti-obesity therapy, back in November. There will be more challengers in the future, but Eli Lilly seems ready to take on all of them, thanks to moves like the one it just made. And beyond its work in this area, the company has a deep lineup and pipeline. It recently acquired a promising mid-stage investigational non-opioid pain medicine. Newer products, like Kisunla for Alzheimer's disease, Ebglyss for eczema, and Jaypirca for cancer, will contribute meaningfully to its top line eventually. Other pipeline assets, such as a gene therapy for one form of deafness, could also make steady clinical and regulatory progress. And amid all that, Eli Lilly continues to grow its revenue at a faster pace than any of its comparable peers. In the first quarter, the company's revenue jumped by 45% year over year to $12.7 billion. Some might point to the threat of tariffs as a reason to stay away from the stock. If President Donald Trump can implement his trade agenda, it might lead to higher costs for the company, eventually resulting in lower profits and margins. However, Lilly has long been expanding its local manufacturing capacity, and it continues to do so, so this isn't an issue that it can't overcome. Considering the strength of its business, deep lineup and pipeline, excellent innovative capabilities, and rapidly growing dividend, Eli Lilly looks like a no-brainer buy. Before you buy stock in Eli Lilly, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Eli Lilly wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,702!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $870,207!* Now, it's worth noting Stock Advisor's total average return is 988% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Prosper Junior Bakiny has positions in Eli Lilly and Novo Nordisk. The Motley Fool has positions in and recommends Amgen. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. Eli Lilly Just Made Another Move to Dominate the Weight Loss Market: Should You Buy the Stock? was originally published by The Motley Fool Sign in to access your portfolio
Yahoo
5 hours ago
- Yahoo
1 Growth Stock Down 9% to Buy Right Now
Eli Lilly's share price is down about 6.4% over the past year. The pharmaceutical giant's weight-loss drugs continue to drive fast revenue and earnings growth. 10 stocks we like better than Eli Lilly › Not many companies that have been around since the late 1800s can claim that they're growth companies. But Eli Lilly (NYSE: LLY) can. However, even growth stocks with long and impressive track records can see their share prices take a breather. Eli Lilly's stock is down about 6.4% over the last year through June 12. Some may worry about such a drop, but I don't believe that's a warning sign for investors. Rather, investors should think of this dip as a buying opportunity. Eli Lilly has two weight-loss drugs on the market, Mounjaro (which also treats type 2 diabetes) and Zepbound. Both can now be classified as blockbuster drugs (which have over $1 billion in annual sales). Demand for the products shows no signs of slowing. First-quarter Mounjaro sales more than doubled year over year from $1.8 billion to $3.8 billion, with management also noting the product's expansion into new geographic markets. Zepbound's sales more than quadrupled from $517.4 million to $2.3 billion. Finding a more convenient way of taking this medication could spur additional demand. Currently, patients inject themselves weekly with the drugs, which has been a deterrent for some wanting to obtain prescriptions. In April, Eli Lilly management announced a successful phase 3 trial of a daily oral treatment for type 2 diabetes and weight loss. The company expects to submit the drug for approval later this year (weight loss) and in 2026 (diabetes). The two products accounted for about 48% of Eli Lilly's most recent quarterly sales and drove most of the top-line growth. With a large and growing market, and the entry of a product that will make it more convenient to take the treatment, that growth should prove sustainable for a long period. Eli Lilly has already been taking market share from chief rival Novo Nordisk (NYSE: NVO). Novo Nordisk has been struggling, and its new treatment failed to meet expectations. Meanwhile, Eli Lilly's existing weight-loss drugs appear to produce better results. In fact, Eli Lilly had difficulty meeting skyrocketing demand in the past. That's a nice problem to have. Eli Lilly's total first-quarter revenue grew 45% year over year to $12.7 billion, and its diluted earnings per share (EPS) under generally accepted accounting principles (GAAP) was $3.06, 23% higher. Management expects this year's EPS to come in at $20.17 to $21.67. While it reduced its guidance from $22.05 to $23.55, the updated figures are still a tremendous increase from the $11.71 a share Eli Lilly earned in 2024. You can't call Eli Lilly shares a bargain based on the stock's trailing price-to-earnings (P/E) ratio. The shares trade at a P/E of 63 compared to the S&P 500 index's 29. Still, a year ago, when the stock price was higher, the P/E ratio stood at 125. Of course, earnings have been growing rapidly. Based on analyst estimates for the next year, Eli Lilly's stock has a forward P/E of 36. Hence, it seems the above-average valuation is justified based on growth expectations. The fast top-line and bottom-line pace doesn't seem likely to subside given Eli Lilly's leadership and potential new products in the fast-growing weight loss category. That presents a good opportunity for growth-seeking investors, and it's why I'd use the stock dip as a buying opportunity. Before you buy stock in Eli Lilly, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Eli Lilly wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $655,255!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $888,780!* Now, it's worth noting Stock Advisor's total average return is 999% — a market-crushing outperformance compared to 174% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Lawrence Rothman, CFA has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. 1 Growth Stock Down 9% to Buy Right Now was originally published by The Motley Fool
Yahoo
a day ago
- Yahoo
The cost of staying alive could become a lot more expensive for millions of Americans because of Trump drug tariffs
Americans would likely pay more for necessary everyday prescription drugs, such as insulin, painkillers, chemotherapy, or antibiotics, if President Donald Trump were to enact tariffs on pharmaceuticals, experts warn. In an effort to incentivize drug manufacturers to bring production back to the United States, Trump has proposed tariffing pharmaceuticals made overseas – which account for an overwhelming majority of everyday medicine used in the U.S. 'We're going to be doing that,' Trump said of pharmaceutical tariffs in April. 'That's going to be like we have on cars. You know we have a 25 percent tariff on cars, we have a 25 percent tariff on steel and aluminum, and that's what the [pharmaceutical] category fits right now.' 'The higher the tariff, the faster they come,' Trump said. But experts say that's not necessarily true and there would be tangible consequences to such action, from higher brand-name drug prices to generic drug shortages. 'If tariffs were applied to prescription drugs, one of the most immediate consequences could be price increases — on prices that we already pay way in excess of other countries,' Dr. Mariana Socal, an associate professor at the Johns Hopkins Bloomberg School of Public Health, said. The U.S. imports a majority of its branded prescription drugs – or medications that are patented with a brand name such as Viagra, Wegovy, or Zoloft – from high-income countries. Dr. Jeromie Ballreich, an associated research professor at Johns Hopkins Bloomberg School of Public Health, said much of the manufacturing comes from Ireland, Germany, and Switzerland because they have favorable tax policies for companies. As a result, adding a tariff would only make it more expensive for pharmacies and insurance companies to keep them in supply. 'We would expect pharma to pass the costs onto the insurers and we would expect insurers to pass the cost onto the individual patients,' Ballreich said. 'So, if there is a 50 percent tariff on your insulin product because it's coming from Ireland, patients in Mississippi who get insulin – they will either be faced with a higher cost when they go up to the pharmacy to fill their insulin or they're going to face a higher indirect cost because the premiums of the insurance plan are going to go up,' he said. Ballreich said a tariff on countries that produce high quantities of branded drugs would put 'pressure' on public insurers like Medicare or Medicaid and private insurers. However, branded drugs only account for roughly 10 to 15 percent of prescriptions. A majority of Americans, up to 90 percent, use generic drugs, often manufactured in India and China, because they're cheaper. Making branded drugs less accessible through tariffs would only increase reliance on generic drugs, which could exacerbate shortages that already impact millions of Americans. '[Shortages] can have very significant implications in day-to-day clinical practice,' Socal said. 'For example, if you are administering chemotherapy for an oncology patient, that may have significant consequences even for the prognosis of that case moving forward.' In 2024, the U.S. experienced a shortage of more than 300 drugs – 70 percent of which were generic prescriptions. Socal said that when patients are not able to access a more affordable version of their prescription, it means they may put their health at risk by skipping a dosage, taking a lower dosage, or not filling their prescription at all. Otherwise, they're forced to turn to the more expensive branded version. 'Those more expensive drugs are not always the best,' Socal said. 'Very frequently, and we saw this with chemotherapy shortages, the available drugs are second-line drugs.' The president has indicated that any negative impact from tariffs may be temporary and worth it to bring manufacturing and jobs back. 'We're doing it because we want to make our own drugs,' Trump said. But Ballreich and Socal are more skeptical. 'Tariffs are a very blunt instrument to incentivize domestic U.S. manufacturing of the branded drugs we use,' Ballreich said. Given pharmaceutical companies have moved outside of the U.S. for tax purposes, Ballreich says tax policy may be a better way to incentivize them, especially since many of those drugs are more difficult to manufacture. 'It's not just a very simple chemical plant; these tend to be very complex,' he said. Socal suggested a better strategy would be to understand where drugs are being manufactured and which ones would make more sense to bring to the U.S. — since even those manufactured locally often rely on certain imported ingredients and materials. 'Having tariffs on pharmaceutical products coming from abroad can actually also hurt our domestic manufacturers,' he says. While the president has not officially implemented any tariff policy on pharmaceuticals yet, he said, in April, that the plan would take effect in the 'not too distant future.'
